Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.94
NBS's Cash to Debt is ranked higher than
60% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. NBS: 1.94 )
NBS' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 1.94

Equity to Asset 0.48
NBS's Equity to Asset is ranked higher than
62% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NBS: 0.48 )
NBS' s 10-Year Equity to Asset Range
Min: -40.98   Max: 0.92
Current: 0.48

-40.98
0.92
F-Score: 4
Z-Score: -2.84
M-Score: -2.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -314.69
NBS's Operating margin (%) is ranked higher than
63% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. NBS: -314.69 )
NBS' s 10-Year Operating margin (%) Range
Min: -10991.67   Max: -27.04
Current: -314.69

-10991.67
-27.04
Net-margin (%) -333.29
NBS's Net-margin (%) is ranked higher than
63% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. NBS: -333.29 )
NBS' s 10-Year Net-margin (%) Range
Min: -13154.35   Max: -33.38
Current: -333.29

-13154.35
-33.38
ROE (%) -93.33
NBS's ROE (%) is ranked higher than
60% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. NBS: -93.33 )
NBS' s 10-Year ROE (%) Range
Min: -578.99   Max: -57.05
Current: -93.33

-578.99
-57.05
ROA (%) -55.94
NBS's ROA (%) is ranked higher than
63% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. NBS: -55.94 )
NBS' s 10-Year ROA (%) Range
Min: -850.61   Max: -18.34
Current: -55.94

-850.61
-18.34
ROC (Joel Greenblatt) (%) -380.15
NBS's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. NBS: -380.15 )
NBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -80050   Max: -46.95
Current: -380.15

-80050
-46.95
Revenue Growth (3Y)(%) -62.40
NBS's Revenue Growth (3Y)(%) is ranked higher than
58% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. NBS: -62.40 )
NBS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 196.7
Current: -62.4

0
196.7
EBITDA Growth (3Y)(%) -11.10
NBS's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NBS: -11.10 )
NBS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56.8   Max: 14.3
Current: -11.1

-56.8
14.3
EPS Growth (3Y)(%) -25.30
NBS's EPS Growth (3Y)(%) is ranked higher than
65% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. NBS: -25.30 )
NBS' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.7   Max: 9.6
Current: -25.3

-52.7
9.6
» NBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NBS Guru Trades in

NBS Guru Trades in

Q3 2013

NBS Guru Trades in Q3 2013

Jim Simons 30,037 sh (New)
» More
Q4 2013

NBS Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.04
NBS's P/B is ranked higher than
91% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. NBS: 2.04 )
NBS' s 10-Year P/B Range
Min: 0.59   Max: 150
Current: 2.04

0.59
150
P/S 6.62
NBS's P/S is ranked higher than
87% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. NBS: 6.62 )
NBS' s 10-Year P/S Range
Min: 0.72   Max: 360.71
Current: 6.62

0.72
360.71
EV-to-EBIT -2.15
NBS's EV-to-EBIT is ranked lower than
51% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NBS: -2.15 )
NBS' s 10-Year EV-to-EBIT Range
Min: -8.1   Max: -0.2
Current: -2.15

-8.1
-0.2
Current Ratio 3.49
NBS's Current Ratio is ranked higher than
68% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. NBS: 3.49 )
NBS' s 10-Year Current Ratio Range
Min: 0.01   Max: 12.92
Current: 3.49

0.01
12.92
Quick Ratio 3.31
NBS's Quick Ratio is ranked higher than
68% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. NBS: 3.31 )
NBS' s 10-Year Quick Ratio Range
Min: 0.01   Max: 12.92
Current: 3.31

0.01
12.92
Days Inventory 36.60
NBS's Days Inventory is ranked higher than
96% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NBS: 36.60 )
NBS' s 10-Year Days Inventory Range
Min: 26.9   Max: 457.38
Current: 36.6

26.9
457.38
Days Sales Outstanding 45.55
NBS's Days Sales Outstanding is ranked higher than
87% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. NBS: 45.55 )
NBS' s 10-Year Days Sales Outstanding Range
Min: 26.85   Max: 4506.17
Current: 45.55

26.85
4506.17

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.40
NBS's Dividend Yield is ranked lower than
84% of the 195 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. NBS: 0.40 )
NBS' s 10-Year Dividend Yield Range
Min: 0.38   Max: 7.04
Current: 0.4

0.38
7.04
Yield on cost (5-Year) 0.40
NBS's Yield on cost (5-Year) is ranked lower than
83% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. NBS: 0.40 )
NBS' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 7.04
Current: 0.4

0.38
7.04
Share Buyback Rate -58.30
NBS's Share Buyback Rate is ranked higher than
55% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: -10.40 vs. NBS: -58.30 )
NBS' s 10-Year Share Buyback Rate Range
Min: -14.5   Max: -150.6
Current: -58.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.30
NBS's Price/Median PS Value is ranked higher than
97% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. NBS: 0.30 )
NBS' s 10-Year Price/Median PS Value Range
Min: 0.05   Max: 1714.29
Current: 0.3

0.05
1714.29
Earnings Yield (Greenblatt) -46.50
NBS's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. NBS: -46.50 )
NBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -46.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8NE1.Germany,
Neostem Inc was incorporated under the laws of the State of Delaware on September 18, 1980. It is engaged in cellular therapy industry. The Company develops novel proprietary cell therapy products. It is engaged in therapies that addresses ischemia through its CD34 Cell Program. AMR-001 is its product candidate in the CD34 Cell Program being developed to treat damaged heart muscle following an acute myocardial infarction. The Company competes with various companies like Lonza Group Ltd. and WuXi AppTec. The Company is subject to various governmental regulatory authorities, as well as private accreditation organizations, oversee and monitor the activities of individuals and businesses engaged in the development, manufacture and delivery of health care products and services.
» More Articles for NBS

Headlines

Articles On GuruFocus.com
"New To The Street"Announces Nationwide Broadcast Dec 03 2014 

More From Other Websites
NEOSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jan 22 2015
NeoStem Announces Addition of Experienced Scientist and Biotechnology Executive Peter G. Traber, MD,... Jan 22 2015
NeoStem Announces Addition of Experienced Scientist and Biotechnology Executive Peter G. Traber, MD,... Jan 22 2015
NeoStem Receives Drug Manufacture License for Irvine Facility Jan 20 2015
NeoStem Receives Drug Manufacture License for Irvine Facility Jan 20 2015
NEOSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jan 16 2015
NEOSTEM, INC. Files SEC form 8-K, Other Events Jan 13 2015
Cryoport Appoints Richard J. Berman to its Board of Directors Jan 13 2015
NeoStem and Invetech Announce Agreement to Develop Closed Processing System for Cell Therapy... Jan 12 2015
Coverage initiated on Neostem by Oppenheimer Jan 09 2015
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Neostem, Inc.... Jan 08 2015
NeoStem, Inc. "Strengthening NeoStem's Executive Management with Two Significant Hires" Jan 07 2015
NEOSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles... Jan 05 2015
NeoStem Strengthens Executive Management With Appointments of David J. Mazzo, PhD as Chief Executive... Jan 05 2015
NeoStem Strengthens Executive Management With Appointments of David J. Mazzo, PhD as Chief Executive... Jan 05 2015
PCT, a NeoStem Company, Presented Lovo® Cell Processing System Data at IBC Life Sciences’... Dec 15 2014
PCT, a NeoStem Company, Presented Lovo(R) Cell Processing System Data at IBC Life Sciences'... Dec 15 2014
NeoStem’s Subsidiary, Progenitor Cell Therapy, Receives AABB Re-Accreditation for its Allendale,... Dec 08 2014
NeoStem's Subsidiary, Progenitor Cell Therapy, Earns AABB Re-Accreditation for Its Allendale, NJ... Dec 08 2014
"New To The Street"Announces Nationwide Broadcast Dec 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK